Within the last quarter, Mirati Therapeutics MRTX has observed the following analyst ratings:
|Bullish||Somewhat Bullish||Indifferent||Somewhat Bearish||Bearish|
These 7 analysts have an average price target of $160.57 versus the current price of Mirati Therapeutics at $59.25, implying upside.
Below is a summary of how these 7 analysts rated Mirati Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
This current average represents a 17.23% decrease from the previous average price target of $194.00.
How Are Analyst Ratings Determined?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.